Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 3/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | DAGLB | Q8NCG7 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7939228 | 1.00 | PREP (0.52) | PREPACE2NPSR1TSHRCYP3A4 | |
| SCHEMBL1873488 | 1.00 | PREP (0.52) | PREPACE2NPSR1TSHRCYP3A4 | |
| SCHEMBL31211830 | 0.93 | F2 (0.50) | PREPACE2RAB9A | |
| SCHEMBL3130196 | 0.91 | PREP (0.50) | PREPACE2NPSR1TSHRCYP3A4 | |
| SCHEMBL3119462 | 0.89 | DAGLB (0.49) | PREPACE2NPSR1TSHRCYP3A4 | |
| SCHEMBL8342143 | 0.89 | DAGLB (0.49) | PREPACE2NPSR1TSHRCYP3A4 | |
| SCHEMBL8342145 | 0.89 | DAGLB (0.49) | PREPACE2NPSR1TSHRCYP3A4 | |
| SCHEMBL1873676 | 0.87 | PREP (0.53) | PREPACE2NPSR1TSHRCYP3A4 | |
| SCHEMBL5786248 | 0.87 | PREP (0.53) | PREPACE2NPSR1TSHRCYP3A4 | |
| SCHEMBL791439 | 0.86 | PREP (0.57) | PREPACE2NPSR1TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4469447-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146989-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-0981526-B1 | NOVEL ANTIDIABETIC COMPOUNDS HAVING HYPOLIPIDAEMIC, ANTIHYPERTENSIVE PROPERTIES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | REDDYS LAB LTD DR (IN) | 2004-02-25 | — | — | EP | disclosed |
| US-6245796-B1 | NERVOUS SYSTEM DISORDERS; SEXUAL DISORDERS; SLEEP DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-12 | — | — | US | disclosed |
| EP-0990650-A1 | TRICYCLIC PYRROLE OR PYRAZOLE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-04-05 | — | — | EP | disclosed |
| US-5889025-A | Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them | REDDY'S RESEARCH FOUNDATION (IN) | 1999-03-30 | — | — | US | disclosed |
| EP-0309766-B1 | N-acylamino acid derivatives and their use | BANYU PHARMA CO LTD (JP) | 1998-04-15 | — | — | EP | disclosed |
| US-5506356-A | RENIN INHIBITORS; HYPOTENSIVE AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-04-09 | — | — | US | disclosed |
| US-5481036-A | RENIN INHIBITORS, HYPOTENSIVE AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-01-02 | — | — | US | disclosed |
| US-5319082-A | N-acylamino acid derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-06-07 | — | — | US | disclosed |
| US-5240924-A | Dipeptide hypotensives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-31 | — | — | US | disclosed |
| US-5122523-A | Hypotensive agents | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-06-16 | — | — | US | disclosed |
| EP-0309766-A2 | N-acylamino acid derivatives and their use | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | ABCG2, F12, CYP2C9 | PREP 2026/4885ACE2 1600/4885NPSR1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.